| Name | Title | Contact Details |
|---|
USAID is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 2001, Regent Surgical Health has led the way in developing and managing successful surgery center partnerships. The ASC model is constantly evolving and Regent positions our facility partners to meet these changing market conditions and succeed. Today, a vast majority of our partnerships are Physician/Hospital Joint Ventures. Our experience has led us to develop proprietary ownership models that give both doctors and hospital administrators what they need to ensure long term clinical and financial success. Our success had earned us a reputation as Joint Venture Specialists. Regent has extensive knowledge of the ASC marketplace. We have found successful financial solutions to increase net revenues rather than using out of network strategies, pioneered new procedures such as spine, cardiology, gastric banding, and knee replacements into the ASC environment, and developed both majority and minority hospital partnerships. At Regent, our track record for successful ASC Turnarounds, De Novos, and Joint Ventures is unmatched.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
EverestLabs is a company that uses AI, robotics, and automation to help material recovery facilities (MRFs) operate more efficiently and enabling CPG brands to exceed their recycled content, EPR and ESG goals.
The MetroHealth System is an essential health system committed to providing health care to everyone in Cuyahoga County, Ohio, and improving the health of the community overall. Its 6,700 employees deliver care to everyone at its main campus, just west of downtown Cleveland, and at more than 20 other MetroHealth locations. It also provides health care at more than 20 additional sites in Cuyahoga County through community partnerships such as the School Health Program. MetroHealth is home to Cuyahoga County`s only verified Level I Adult Trauma Center and Level II Pediatric Trauma Center, and it is the only adult and pediatric burn center in the state of Ohio verified by the American Burn Association and the Committee on Trauma of the American College of Surgeons. In the past year, MetroHealth provided more than one million patient visits in its hospital and health centers. MetroHealth also is an academic medical center committed to teaching and research; each of its active physicians holds a faculty appointment at Case Western Reserve University School of Medicine. MetroHealth has earned Magnet status, which places it in the top 6 percent of all hospitals nationwide for nursing excellence. The MetroHealth System makes every effort to ensure that in every phase of the recruitment and selection process, equal employment is provided to all individuals, regardless of race, color, gender, sex, age, creed, disability, national origin or citizenship, veteran`s status, sexual orientation, gender identity, religious affiliation, socio-economic standing, pregnancy and/or genetic information, and any other protected characteristic. MetroHealth`s mission is, “Leading the way to a healthier you and a healthier community through service, teaching, discovery and teamwork.”